Three exceptional postdoctoral researchers will each receive a $300,000 grant, awarded over two years, to support their innovative biomedical research relevant to IBD.
Highlights from our conversation with Gary Mathias of Thetis Pharmaceuticals, a clinical-stage biopharmaceutical company developing alternatives to immuno-suppressive therapies.
Explore highlights from our conversation with Julie Saiki, PhD, of Azora Therapeutics, a clinical-stage biopharmaceutical company developing an alternative to immuno-suppressive therapies.
Explore highlights from our conversation with Steve Axelrod, PhD, President and CEO at G-Tech Medical, which has developed a non-invasive technology to monitor gut motility.
The Rainin Foundation’s early and ongoing investments in three companies help illustrate the opportunities and challenges in this sector.
The 2026 Symposium will be held in San Francisco on July 19-21, convening researchers, clinicians and trainees working across disciplines to accelerate progress in preventing and treating IBD.
Our 2025 Innovations Symposium drew researchers, clinicians and industry professionals for two and a half days of presentations and poster sessions to encourage new ideas in Inflammatory Bowel Disease research.
The 2025 Innovator Awards grantee projects explore new ways to reduce inflammation and restore gut health, targeted treatment options with fewer side effects and the chance for lasting healing, and the gut-brain connection.
The Kenneth Rainin Foundation invites Letters of Inquiry for our Innovator Awards Program from August 15 through September 30, 2025.
Join fellow researchers, trainees and clinicians from around the world for the Kenneth Rainin Foundation’s 2025 Innovations Symposium.
